Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Hemostemix Inc
HMTXF
Primary Symbol:
V.HEM
Healthcare
Biotechnology
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including...
angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:HEM)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 30, 2022 7:31am
Efficacy of NCP-01 a futuristic product by Hemostemix
Neuropathic pain syndromes can be treated with NCP-01 and its autologous stem cell technology, which can treat disorders of the central and peripheral nervous systems. Spinal cord injury, chronic
...more
(13)
•••
trade007
X
View Profile
View Bullboard History
Post by
trade007
on Jun 30, 2022 7:24am
$HMTXF Average Volume Rate
Hemostemix Inc. is seen to be doing well in the OTC market with its ticker symbol $HMTXF. The average volume in the last 30 days is recorded to be above $21K.
Join Pulsar Helium on the Ground in Minnesota for a Historic Reservoir Flow Test
posted May 03, 2024 9:00am by
Pulsar Helium Inc.
-
|
In recognition of the recent docu-film highlighting the importance of helium in healthcare we are offering investors an opportunity to join Pulsar on the ground in Minnesota for this month's historic reservoir flow tests. CLICK HERE ...read more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 29, 2022 2:51pm
$HMTXF average volume expenditure analysis
$HMTXF offers a sum of approx 22,798 for daily trade and investor related activities on the OTC market which is likely to vary as per the market’s demeanor.
(6)
•••
Tradeconnects
X
View Profile
View Bullboard History
Post by
Tradeconnects
on Jun 29, 2022 2:46pm
$HEM multiplying with consummate elegance
$HEM has been on quite an impressive venture, the stock has been seen to have ground breaking potential by the investors and is a worthy investment per se, shares are trading at $0.255 with a major
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 29, 2022 2:34pm
regains lawful possession of all its missing intellectual pr
All the intellectual data including all phase 2 clinical trial data, all the historical data from hemostemix Israel, and the randomized table required to analyze North-American and South-African ACP
...more
(17)
•••
christiano
X
View Profile
View Bullboard History
Post by
christiano
on Jun 29, 2022 2:15pm
$HMTXF Upper and Lower Price in the Last 52 weeks
Hemostemix Inc. holds a significant position over the OTC market with its greater difference between the lower and higher ranges of trading, which is $0.0991-$0.3279 in the last 52 weeks.
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 29, 2022 1:00pm
Hemostemix dissolves all pending lawsuits with Aspire health
The long awaited moment for hemostemix has finally come. The company just got done with all the pending legal proceedings regarding the un-authorized possession of ACP-01’s clinical trial data has
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 29, 2022 12:38pm
Hemostemix hires new financial advisor to the family
Mr. Rick Groome who has effectively settled 2 securities firm, helping many successful biotechnology companies in providing funds over the last three decades has joined hemostemix as a special
...more
(3)
•••
tradeviewww
X
View Profile
View Bullboard History
Post by
tradeviewww
on Jun 28, 2022 3:25pm
$HMTXF about to issue the global field use license of NCP-01
Hemostemix will grant PreCerv a global field of use licence for NCP-01 and its autologous stem cell technology to treat central and peripheral nervous system diseases. Such as Neuropathic pain
...more
(17)
•••
christiano
X
View Profile
View Bullboard History
Post by
christiano
on Jun 28, 2022 3:25pm
$HEM announcement related to the Stock Options Grant
Hemostemix Inc. announced that in accordance with its stock option plan, it has granted on February 28, 2022, subject to regulatory approval, a total of 1,494,269 stock options to purchase common
...more
(7)
•••
TRADERCONNECTS
X
View Profile
View Bullboard History
Post by
TRADERCONNECTS
on Jun 28, 2022 2:50pm
$HMTXF a praiseworthy stock multiplying in heavily
$HMTXF has been on quite an impressive venture, the stock is seen to have much potential by the investors and is a worthy investment, shares are trading at $0.1960 with a 0.20% jump in value.
(17)
•••
christiano
X
View Profile
View Bullboard History
Post by
christiano
on Jun 28, 2022 1:31pm
$HEM Market Insight
Hemostemix is a clinical-stage biotechnology company trading in TSX-V with ticker symbol $HEM is currently sitting at $0.255 with volume of $8.62K+.
(17)
•••
christiano
X
View Profile
View Bullboard History
Post by
christiano
on Jun 28, 2022 1:30pm
Hemostemix Inc. Market Graph
Hemostemix Inc. holds a significant role in TSX-V with its greater difference between the lower and higher range of trading today is $0.255-$0.285. In the last 52 weeks it is $0.13-$0.42.
(17)
•••
christiano
X
View Profile
View Bullboard History
Post by
christiano
on Jun 28, 2022 1:21pm
$HEM Stock Analysis and Evaluation
Hemostemix Inc. is an emerging biotechnology company listed on TSX-V with the ticker symbol $HEM traded today at price of $0.255 per share.
(24)
•••
robert345
X
View Profile
View Bullboard History
Post by
robert345
on Jun 28, 2022 1:02pm
$HEM announced amalgamation of an entirely owned subsidiary
The business is happy to announce that PreCerv Inc. ("PreCerv") has been incorporated as a completely owned subsidiary. A worldwide field of use licence for NCP-01 and its autologous stem
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results
Drill Permit Approval Received for New Mexico Lithium Project
This profitable gold stock is on its way up
An Opportunity to Join Pulsar Helium on the Ground in Minnesota for a Historic Reservoir Flow Test
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company